Autonomix Medical (AMIX) Set to Post Quarterly Earnings on Wednesday

Autonomix Medical (NASDAQ:AMIX) is projected to release its Q2 2027 resultson Wednesday, November 11th. Analysts expect Autonomix Medical to post earnings of ($2.62) per share for the quarter. Investors can check the company’s upcoming Q2 2027 earnings report page for the latest details on the call scheduled for Monday, November 9, 2026 at 9:30 AM ET.

Autonomix Medical (NASDAQ:AMIX) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($5.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.40) by $1.38. On average, analysts expect Autonomix Medical to post ($20.17) EPS for the current fiscal year and ($17.44) EPS for the next fiscal year.

Autonomix Medical Price Performance

Shares of AMIX stock traded up $0.07 during trading hours on Wednesday, hitting $1.73. 9,644 shares of the company’s stock were exchanged, compared to its average volume of 1,388,906. The stock’s 50-day moving average is $3.68 and its 200-day moving average is $6.73. The stock has a market cap of $1.67 million, a price-to-earnings ratio of -0.04 and a beta of -0.70. Autonomix Medical has a 52 week low of $1.63 and a 52 week high of $32.55.

Analyst Upgrades and Downgrades

AMIX has been the topic of several research reports. Wall Street Zen upgraded shares of Autonomix Medical from a “strong sell” rating to a “sell” rating in a research report on Saturday, October 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Autonomix Medical in a research report on Monday, October 26th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $42.00.

Autonomix Medical Company Profile

Autonomix Medical, Inc is a medical device company developing catheter-based technologies for the detection and treatment of conditions involving the peripheral nervous system. The company’s platform is designed to identify neural signals in real time, with the goal of helping physicians locate and selectively treat targeted nerves during minimally invasive procedures.

Autonomix’s lead development program is focused on pain associated with pancreatic cancer. Its technology is intended to support targeted nerve ablation, potentially offering an alternative approach for managing pain while reducing the need for more extensive procedures.